COVID-19.рф: ИНФОРМАЦИЯ ПРОТИВ ПАНДЕМИИ

Поиск по репозиторию

Статья

Inhibition of feline (FIPV) and human (SARS) coronavirus by semisynthetic derivatives of glycopeptide antibiotics

J. Balzarini, E. Keyaerts, L. Vijgen, H. Egberink, C. De, R. Van, S. Printsevskaya, E. Olsufyeva, S. Solovieva, M. Preobrazhenskaya,
2021
https://doi.org/10.1016/j.antiviral.2006.03.005

Various semisynthetic derivatives of glycopeptide antibiotics including vancomycin, eremomycin, teicoplanin, ristocetin A and DA-40926 have been evaluated for their inhibitory activity against feline infectious peritonitis virus (FIPV) and human (SARS-CoV, Frankfurt-1 strain) coronavirus in cell culture in comparison with their activity against human immunodeficiency virus (HIV). Several glycopeptide derivatives modified with hydrophobic substituents showed selective antiviral activity. For the most active compounds, the 50% effective concentrations (EC50) were in the lower micromolar range. In general, removal of the carbohydrate parts of the molecules did not affect the antiviral activity of the compounds. Some compounds showed inhibitory activity against both, whereas other compounds proved inhibitory to either, FIPV or SARS-CoV. There was no close correlation between the EC50 values of the glycopeptide derivatives for FIPV or SARS-CoV. © 2006 Elsevier B.V. All rights reserved.

Цитирование

Похожие публикации

Inhibition of the SARS-CoV-2 RNA-Dependent RNA polymerase by natural bioactive compounds: Molecular docking analysis
N. Abd El-Aziz, O. Eldin Awad, M. Shehata,
Computational Modeling of the SARS-CoV-2 Main Protease Inhibition by the Covalent Binding of Prospective Drug Molecules
A. Nemukhin, B. Grigorenko, I. Polyakov,
Computational Modeling of the SARS-CoV-2 Main Protease Inhibition by the Covalent Binding of Prospective Drug Molecules
A. Nemukhin, B. Grigorenko, I. Polyakov,

Источник

Версии

  • 1. Version of Record от 2021-04-27

Метаданные

Об авторах
  • J. Balzarini
    Rega Institute for Medical Research, K.U. Leuven, Minderbroedersstraat 10, B-3000 Leuven, Belgium
  • E. Keyaerts
    Institute of Virology, Faculty of Veterinary Medicine, University of Utrecht, Utrecht, Netherlands
  • L. Vijgen
    Gause Institute of New Antibiotics, Russian Academy of Medical Sciences, Moscow, Russian Federation
  • H. Egberink
  • C. De
  • R. Van
  • S. Printsevskaya
  • E. Olsufyeva
  • S. Solovieva
  • M. Preobrazhenskaya
Название журнала
  • Antiviral Research
Том
  • 72
Выпуск
  • 1
Страницы
  • 20-33
Ключевые слова
  • antivirus agent; cytostatic agent; da 40; dmd 40; eremomycin; eremomycin derivative; polypeptide antibiotic agent; ristocetin; teicoplanin; teicoplanin derivative; unclassified drug; vancomycin; vancomycin derivative; antiviral activity; article; concentration response; Coronavirus; correlation function; drug screening; drug selectivity; hydrophobicity; in vitro study; nonhuman; priority journal; SARS coronavirus; Animals; Anti-Bacterial Agents; Cell Line; Coronavirus, Feline; Cytopathogenic Effect, Viral; Glycopeptides; Humans; SARS Virus; Teicoplanin; Vancomycin; Virus Inactivation; Virus Replication; Coronavirus; Felidae; Feline infectious peritonitis virus; Human immunodeficiency virus; SARS coronavirus
Тип документа
  • journal article
Источник
  • scopus
COVID-19.рф: Информация против пандемии

Адрес: 115114, Москва, ул. Летниковская, д. 4, стр.5, офис 2.4
тел.\факс: +7(499)754-99-94, доб. 502
e-mail: covid19@neicon.ru

Проект реализуется с использованием гранта Президента Российской Федерации на развитие гражданского общества, предоставленного Фондом президентских грантов.

Содержимое сайта, если не указано иное, опубликовано в соответствии с лицензией Creative Commons «Attribution» («Атрибуция») 4.0 Всемирная (CC BY 4.0). Права на материалы, переданные партнерами проекта, принадлежат их правообладателям.

© 2025 NEICON